ACTSI Investigator Dr. Guillermo Umpierrez in the News

Guillermo Umpierrez, MD, ACTSI investigator, professor in the Endocrinology Division of Emory University, director of the Grady Memorial Hospital Clinical Research Network, ACTSI, and director of the Diabetes and Endocrinology section at Grady

Umpierrez is principal investigator of an investigator-initiated sponsored clinical trial funded by AstraZeneca Pharmaceuticals entitled, “Exenatide inpatient trial: a randomized controlled pilot trial on the safety and efficacy of Exenatide (Byetta®) therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes.”

The Georgia House of Representatives, by Resolution, honored Umpierrez with the "Inspiring Mentor Award." He directs Diabetes and Endocrinology at Grady Hospital and leads the Emory Latino Diabetes Education Program, the first nationally accredited all-Spanish diabetes education program dedicated to providing diabetes education and lifestyle intervention to Latinos in Georgia.

Umpierrez is site principal investigator of two clinical trials: the first, funded by Regeneron Pharmeceuticals, is entitled “A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of REGN1193 in Patients with Type 2 Diabetes Mellitus.” The second, funded by NIDDK through a subcontract with the Joslin Diabetes Center, is entitled “PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in Type 1 Diabetes.”

Umpierrez also received funding from the American Diabetes Association for a clinical trial entitled, “A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Long-Term Care Residents with Type 2 Diabetes.”

Recent Publications

“Iatrogenic Hypoglycemia and Quality of Life in Patients with Type 2 Diabetes Mellitus.” Rev Clin Esp. 2015 Mar;215(2):104-6.

“Perioperative Hyperglycemia and Risk of Adverse Events Among Patients With and Without Diabetes.” Ann Surg. 2015 Jan;261(1):97-103.

“A Quadruply-Asymmetric Sigmoid to Describe the Insulin-Glucose Relationship during Intravenous Insulin Infusion.” J Healthc Eng 2014;5(1):23-54.

“Hospital discharge algorithm based on admission HbA(1c) for the management of patients with type 2 diabetes.” Diabetes Care. 2014 Nov. 37(11):2934-2939. 

“Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3).” Diabetes Care 2014 May 19. pii: DC_132759. [Epub ahead of print].

“Health literacy, self-efficacy, food label use, and diet in young adults.” Am J Health Behav. 2014 May;38(3):331-9.

“Sulfonylureas: a new look at old therapy.” Curr Diab Rep 2014 Apr;14(4):473. doi: 10.1007/s11892-014-0473-5.

“Glucose Variability Is an Independent Predictor of Mortality in Hospitalized Patients Treated with Total Parenteral Nutrition.”  Endocr Pract 2014 Jan-Feb;20(1):41-5.

“Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.” J Diabetes Complications 2013 Nov-Dec;27(6):637-41.